Successful treatment of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic stem cell transplantation with colistin and amikacin inhalation therapy

J Infect Chemother. 2022 Jan;28(1):91-94. doi: 10.1016/j.jiac.2021.08.023. Epub 2021 Sep 10.

Abstract

Pseudomonas aeruginosa is a Gram-negative bacillus that often causes severe infections during immunosuppression in patients with hematologic malignancies. P. aeruginosa can easily acquire drug resistance, and often develops into multidrug-resistant P. aeruginosa (MDRP). Although many antibiotics are used in combination to treat MDRP infections, colistin and amikacin are less likely to be transferred to the lungs, and inhalation therapy may be used. Herein, we report a Case of pneumonia caused by MDRP after allogeneic hematopoietic stem cell transplantation (HSCT) treated with inhaled colistin and amikacin. This 61-year-old female patient was diagnosed with myelodysplastic syndromes and underwent allogeneic HSCT from an 8/8 HLA-matched unrelated donor after reduced-intensity conditioning. On the day of the stem cell infusion, the patient's sputum culture was found to be positive for MDRP. The patient subsequently developed bacteremia, pneumonia, and lung abscess caused by MDRP, and we administered multidrug antibiotic therapy including colistin and amikacin inhalation therapy. The patient's blood cultures were subsequently turned negative, and the lung abscess disappeared. To our knowledge, this is the first case of MDRP pneumonia after HSCT in which colistin and amikacin inhalation therapy was effective.

Keywords: Hematopoietic stem cell transplantation; Multidrug-resistant Pseudomonas aeruginosa; Myelodysplastic syndromes.

Publication types

  • Case Reports

MeSH terms

  • Amikacin / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Colistin / therapeutic use
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Middle Aged
  • Pneumonia* / drug therapy
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa
  • Respiratory Therapy

Substances

  • Anti-Bacterial Agents
  • Amikacin
  • Colistin